Munit is a world-class provider of specialised micronization services specifically engineered for respiratory products, encompassing inhalation powders for both Metered-Dose Inhalers (MDI) and Dry Powder Inhalers (DPI). Our advanced technology and state-of-the-art facilities enable us to micronize Active Pharmaceutical Ingredients (APIs) and Highly Potent Active Pharmaceutical Ingredients (HPAPIs) with exceptional precision and unwavering consistency. This ensures optimal performance and therapeutic efficacy crucial for lung-targeted drug delivery.
Micronization of these lung-targeted APIs and HPAPIs is fundamental for effective drug delivery. By precisely reducing particle size to the critical 1-5 micron range, drug particles can efficiently reach the target area within the lungs, thereby significantly increasing bioavailability and overall therapeutic efficacy. This approach is indispensable for patients managing respiratory diseases such as asthma, Chronic Obstructive Pulmonary Disease (COPD), and cystic fibrosis.
Our commitment to stringent protocols and advanced analytical capabilities guarantees consistent and precise particle size distributions. This rigorous approach ensures that our respiratory products consistently meet the highest safety and efficacy standards, ultimately achieving optimal drug delivery and therapeutic outcomes for patients.